| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Disialyllacto-N-tetraose targets the intestinal epithelium, where it prevents necrotizing enterocolitis (NEC) in neonates. As a human milk oligosaccharide, it may modulate the intestinal microbiome, enhance intestinal barrier function, or exert anti-inflammatory effects in the neonatal gut. However, specific molecular targets have not been extensively characterized.
|
|---|---|
| ln Vitro |
In vitro, Disialyllacto-N-tetraose is a human milk oligosaccharide. It may modulate intestinal epithelial cell function, inhibit bacterial adhesion, or exert anti-inflammatory effects in intestinal cell models. However, detailed in vitro activity data including EC₅₀ values have not been extensively published. The compound is used as a reference molecule in oligosaccharide analysis.
|
| ln Vivo |
In vivo, Disialyllacto-N-tetraose (300 µM, po in formula milk for 3 days) prevents necrotizing enterocolitis (NEC) in Sprague-Dawley rat models. This demonstrates that the compound has significant protective effects against NEC in neonatal animals. The compound is a human milk oligosaccharide used in neonatal health research.
|
| Enzyme Assay |
In vitro assays for Disialyllacto-N-tetraose are not extensively documented. As a human milk oligosaccharide, potential assays could include evaluation of its effects on intestinal epithelial cell barrier function, anti-inflammatory activity in intestinal immune cells, or inhibition of bacterial adhesion to intestinal cells. The compound's structure can be confirmed by NMR and MS. Purity is ≥98%.
|
| Cell Assay |
In vitro cellular assays for Disialyllacto-N-tetraose could include evaluation of its effects on intestinal epithelial cells (such as Caco-2 cells). Cells are treated with the compound and barrier function (measured by TEER), cytokine production, or bacterial adhesion is assessed. The compound is a human milk oligosaccharide.
|
| Animal Protocol |
In vivo animal experiments for Disialyllacto-N-tetraose have been conducted in neonatal rat models of necrotizing enterocolitis. Rats are administered the compound (300 µM) in formula milk for 3 days. Endpoints include NEC incidence and severity, intestinal histopathology, and inflammatory markers. The compound prevents NEC in neonatal rats.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Disialyllacto-N-tetraose are characteristic of complex oligosaccharides. The compound has a molecular weight of approximately 1290.14 g/mol and a molecular formula of C₄₈H₇₉N₃O₃₇. As a large, polar oligosaccharide, it is expected to have limited oral bioavailability and is primarily active in the gastrointestinal tract. Storage: solid at room temperature.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Disialyllacto-N-tetraose has not been extensively documented. As a human milk oligosaccharide, it is expected to have a favorable safety profile. The compound is used in neonatal health research. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Disialyllacto-N-tetraose (CAS# 61278-38-4, molecular formula C₄₈H₇₉N₃O₃₇, molecular weight ~1290.14) is a human milk oligosaccharide that prevents necrotizing enterocolitis in neonatal rats. Also known as DSLNT. Used as a reference molecule in milk oligosaccharide analysis. No clinical trials or regulatory approvals have been identified. Purity ≥98%.
|
| Molecular Formula |
C48H79N3O37
|
|---|---|
| Molecular Weight |
1290.14
|
| Exact Mass |
1289.44
|
| CAS # |
61278-38-4
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
1679.6ºC at 760 mmHg
|
| Flash Point |
969.6ºC
|
| SMILES |
CC(N[C@@H]1[C@@H](O)C[C@@](OC[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](NC(C)=O)[C@@H](O[C@H]4[C@H](O)[C@@H](O[C@]5(C(O)=O)C[C@H](O)[C@@H](NC(C)=O)[C@@H](O5)[C@H](O)[C@H](O)CO)[C@@H](O)[C@H](O4)CO)[C@H](O)[C@H](O3)CO)[C@@H](O)[C@H](O2)CO)[C@H](O)[C@@H](O)C=O)(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7751 mL | 3.8755 mL | 7.7511 mL | |
| 5 mM | 0.1550 mL | 0.7751 mL | 1.5502 mL | |
| 10 mM | 0.0775 mL | 0.3876 mL | 0.7751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
